The use of melatonin as a neuroprotector in the therapy of ischemic stroke
https://doi.org/10.21518/2079-701X-2019-18-18-24
Abstract
Statistics of the World Health Organization (WHO) show that the cerebrovascular disease is the second most frequent cause of death and the third – as the main disabling factor in the working age population. Timely treatment is the key to quickly recovering ischemic tissue. According to the different ischemic cascade stages, the variety of the treatment combinations are proposed. American Stroke Association guidelines 2018 contains no neuroprotectors. In this regard, there remains a need for a biochemical agent successfully blocking one or more stages of the ischemic cascade, preventing cell apoptosis. Melatonin is also considered as such substance due to its neuroprotective properties. The main function of melatonin is the regulation of the sleep-wake cycle. The nuclear and membrane receptors in various organs determines other biological effects of this hormone. The ability of melatonin to regulate the blood pressure, oncogenesis, ovaries cycle, retina function and differentiation of osteoblasts was found. The significant neuroprotective potential of melatonin is realized through the antioxidant, anti-excitotoxic and anti-inflammatory properties. The positive effect on the ischemic lesion size and stroke-related pathological conditions (delirium, insomnia) has been demonstrated both in animal experiments and in clinical studies.
About the Authors
M. G. Poluektov
Federal State Autonomous Educational of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Mikhail G. Poluektov, neurologist, Associate Professor, Chair of Nervous Diseases and Neurosurgery at the Faculty of General Medicine
11, Rossolimo St., Moscow, 119021
A. M. Narbut
Federal State Autonomous Educational of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Anna M. Narbut, 4th student Faculty of General Medicine (International School «Medicine of the Future»)
11, Rossolimo St., Moscow, 119021
N. A. Shuvakhina
Federal State Autonomous Educational Institution of Higher Education «Russian Peoples’ Friendship University»
Russian Federation
Russian Federation
Natal’ya A. Shuvakhina, Cand. of Sci. (Med.), Assistant Professor, Assistant Professor of Chair for Nervous Diseases and Neurosurgery, Faculty of Medicine
6 MiklukhoMaklaya St., Moscow, 117198
References
1. Piradov M.A, Maksimova M.Yu., Tanashyan M.M. Stroke: stepwise instruction. Moscow: GEOTARMedia; 2019. (In Russ.) doi: 10.33029/97044910-3-ins-2019-1-272.
2. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva, World Health Organization; 2018. Available at: http://terrance.who.int/ mediacentre/data/ghe/GlobalCOD_method_2000_2016.pdf?ua=1.
3. Ramos E., Patiño P., Reiter R.J., Martín E.G., Marco-Contelles J., Parada E. et al. Ischemic brain injury: new insights on the protective role of melatonin. Free Radic Biol Med. 2017;(104):3253. doi: 10.1016/j.freeradbiomed.2017.01.005.
4. Roach E., Bettermann K., Biller J. Pathophysiology of Ischemic Stroke. In: Toole’s Cerebrovascular Disorders. Cambridge University Press; 2010:60-74. doi: https://doi. org/10.1017/CBO9781139644235.007 .
5. Powers W.J., Rabinstein A.A., Ackerson T., et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46e110. doi: 10.1161/STR.0000000000000158.
6. Ziganshina L.E., Abakumova T., Vernay L. Cerebrolysin for acute ischemic stroke. Cochrane Database of Systematic Reviews. 2017;(4):CD007026. doi: 10.1002 / 14651858. CD007026. pub4.
7. Harpsoe N.G., Andersen L.P., Gogenur I., Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. doi: 10.1007/ s00228-015-1873-4.
8. Grivas T.B., Vasilidis E.S., Triantafyllopoulos G., Kaspiris A., Burwell R.G. Age variations of melatonin level and its hormesis; implications for AIS and osteoporosis. Scoliosis. 2009;4(Suppl 2):O8. 10.1186/1748-7161-4-S2-O8.
9. Poluektov M.G., Tsenteradze S.L. The possibility of using melatonin in ischemic stroke. Pharmateca = Farmateka. 2013;(7):31-35. (In Russ.) Available at: https://pharmateca.ru/ru/ archive/article/11671.
10. Bubenik G.A. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol. 2008;59(2):33–51. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18812627 .
11. Svistunov A.A., Osadchuk M.A., Osadchuk A.M. Melatonin and its therapeutic prospects in gastroenterology. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):6-12. (In Russ.) https:// doi.org/10.22416/1382-4376-2016-26-5-6-12.
12. Tordjman S., Chokron S., Delorme R., Charrier A., Bellissant E., Jaafari N., Fougerou C. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434-443. doi: 10.2174/1570159X1 4666161228122115.
13. DeVera C., Bada K., Tosini G. Retinal circadian clocks are major players in the modulation of retinal functions and photoreceptor viability. Yale J Biol Med. 2019;92(2):233-240. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31249484.
14. Hardeland R. Melatonin and retinoid orphan receptors: Demand for new interpretations after their exclusion as nuclear melatonin receptors. Melatonin Research. 2018;1(1):78-93. doi: 10.32794/mr11250005.
15. Tamura H., Nakamura Y., Korkmaz A., Manchester L.C., Tan D.-X., Sugino N. et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertility and Sterility. 2009;92(1):328-343. doi: 10.1016/j. fertnstert.2008.05.016.
16. Li H., Wang Y., Feng D., Liu Y., Xu M., Gao A. et al. Alterations in the time course of expression of the Nox family in the brain in a rat experimental cerebral ischemia and reperfusion model: effects of melatonin. J Pineal Res. 2014;57(1):110-119. doi: 10.1111/jpi.12148.
17. Han F., Chen Y.X., Lu Y.M., Huang J.Y., Zhang G.S., Tao R.R., Ji Y.L., Liao M.H., Fukunaga K., Qin Z.H. Regulation of the ischemia-induced autophagy-lysosome processes by nitrosative stress in endothelial cells. J Pineal Res. 2011;51(1):124-135. doi: 10.1111/j.1600-079X.2011.00869.x.
18. Koh P.O. Melatonin regulates the calciumbuffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J Pineal Res. 2012;53(4):358-365. doi: 10.1111/j.1600-079X.2012.01005.x.
19. Koh P. O. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J Vet Med Sci. 2008;70(7):747-750. doi: 10.1292/ jvms.70.747 .
20. Yang Y., Jiang S., Dong Y., Fan C., Zhao L., Yang X., Li J. et al. Melatonin prevents cell death and mitochondrial dysfunction via a SIRT1dependent mechanism during ischemic-stroke in mice. J Pineal Res. 2015;58(1):61-70. doi: 10.1111/jpi.12193.
21. Pallab B., Kumar P.A., Sudip P., Ranjana P. Melatonin renders neuroprotection by Protein Kinase C mediated Aquaporin-4 inhibition in animal model of focal cerebral ischemia. Life Sciences. 2014;100(2):97-109. doi: 10.1016/j. lfs.2014.01.085.
22. Ueda Y., Masuda T., Ishida A., Misumi S., Shimizu Y., Jung C.G. et al. Enhanced electrical responsiveness in the cerebral cortex with oral melatonin administration after a small hemorrhage near the internal capsule in rats. J Neurosci Res. 2014;92(11):1499-1508. doi: 10.1002/jnr.23434.
23. Kovaleva N.S., Balyazin V.A. Analysis of melaxen effectiveness in the treatment of ischemic stroke using quantitative electroencephalography. Polenov’s readings: vseros. scientific. pract. Conf. 2010. 1: 45-46. (In Russ.) Available at: https://www.dissercat.com/content/ispolzovanie-kolichestvennoi-elektroentsefalografiipri-ishemicheskom-insulte-v-usloviyakh-p/ read
24. Levin Ya.I. Melatonin and vascular diseases of the brain. RMZH =RMJ. 2008;(26):1732-1734. (In Russ.) Available at: http://www.fesmu.ru/ elib/Article.aspx?id=196338
25. Kostenko E.V. Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(3):56-64. (In Russ.) doi: 10.17116/jnevro20171173156-64.
26. Vinogradov O.I., Ivanova D.S., Davidov N.P., Kuznetsov A.N. Melatonin in the correction of sleep in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(6):86-89. (In Russ). doi: 10.17116/ jnevro20151156186-89.
27. Ohta T., Murao K., Miyake K., Takemoto K. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1107-1110. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.012.
28. Aly H., Elmahdy H., El-Dib M., Rowisha M., Awny M., El-Gohary T. et al. Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J Perinatol. 2015;35(3):186-191. doi: 10.1038/jp.2014.186.
Review
For citations:
Poluektov MG, Narbut AM, Shuvakhina NA. The use of melatonin as a neuroprotector in the therapy of ischemic stroke. Meditsinskiy sovet = Medical Council. 2019;(18):18-24. (In Russ.) https://doi.org/10.21518/2079-701X-2019-18-18-24
Views:
1461
Email this article 